• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

3

CATEGORIES

  • 5
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1

PRICE

2
4
8
10

PUBLISHED

1
1
2
10

PRODUCT TYPE

6
4

Search "Diabetes R & D Pipeline: DGAT1 Inhibitors" returned 10 results.

PRODUCT TITLE
Competitor Analysis: Emerging Diabetes Drugs Competitor Analysis: Emerging Diabetes Drugs - Product Thumbnail Image

Competitor Analysis: Emerging Diabetes Drugs

The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment...

April 2011
FROM
VIA Pharmaceuticals, Inc. - Product Pipeline Review - 2012 VIA Pharmaceuticals, Inc. - Product Pipeline Review - 2012 - Product Thumbnail Image

VIA Pharmaceuticals, Inc. - Product Pipeline Review - 2012

VIA Pharmaceuticals, Inc. – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “VIA Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the...

November 2012
FROM
Competitor Analysis - Targeted Therapy of Obesity Competitor Analysis - Targeted Therapy of Obesity - Product Thumbnail Image

Competitor Analysis - Targeted Therapy of Obesity

The present Competitive Intelligence Report about Targeted Therapy of Obesity provides a competitor evaluation in the field of novel molecules being developed for treatment of obesity as of March 2011...

March 2011
FROM
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy. Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy. - Product Thumbnail Image

Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.

Introduction Datamonitor forecasts the non-insulins antidiabetics market to grow to $18.8 billion in 2019 for the seven major markets, with pipeline products contributing 39% of sales. GLP-1 agonists...

December 2010
FROM
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers - Product Thumbnail Image

Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers

Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy The non-insulins antidiabetics market is forecast to grow to $18 8 billion...

December 2010
FROM
VIA Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 VIA Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 - Product Thumbnail Image

VIA Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

VIA Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “VIA Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on...

November 2010
FROM

VIA Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

VIA Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “VIA Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on...

November 2010
FROM
Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2012 Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2012 - Product Thumbnail Image

Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Ligand Pharmaceuticals, Inc. – Product Pipeline Review – 2012 Summary Global Markets Direct’s pharmaceuticals report, “Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data...

August 2012
FROM

Dyslipidemia - Pipeline Review, H2 2014

Dyslipidemia - Pipeline Review, H2 2014 Summary This, ‘Dyslipidemia - Pipeline Review, H2 2014’, provides an overview of the Dyslipidemia’s therapeutic pipeline. This report provides comprehensive...

July 2014
FROM

Lipid Disorders - Pipeline Review, H1 2014

Lipid Disorders - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Lipid Disorders - Pipeline Review, H1 2014’, provides an overview of the Lipid Disorders’s therapeutic pipeline. This...

May 2014
FROM
Loading Indicator